Overview
Financials
Revenue history (in k)
Filing timeliness
Financial statements were filed on time, on average 87 days early.
- 202511/05/2026
- 202425/03/2025
- 202326/03/2024
- 202204/04/2023
- 202127/06/2022
- 202025/06/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Offer
- Skin-repair hydrogel
- Repairing and soothing emollient
- Gel for skin problems
- Regenerating and soothing cream
- Menopause symptom preparation
- Urinary incontinence preparation
Website technology
- Website
- WordPress
- Analytics and marketing
- Google Analytics
Trademarks
DEEP Pharma holds 8 active trademarks registered with the Polish Patent Office. 4 marks have expired or were not registered. The first mark was filed in 2017.
| Mark | Protected until | |
|---|---|---|
| Immunox(word) | Oct 16, 2027 | |
| Aroma Help(word) | Jun 28, 2027 | |
| Promeno Forte(word) | Jun 28, 2027 | |
| Tussi Care(word) | Jun 28, 2027 | |
| Tussicare(word) | Jun 28, 2027 |
Authorized Representatives
Manner of representation
The company may be represented by the President of the Management Board acting independently. Another member of the management board may represent the company only jointly with a commercial proxy.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Adam Bieniakage 39 | 47 | $634.79 | 47% |
Krzysztof Bieniakage 36 | 38 | $513.24 | 38% |
Jolanta Furmanage 58 | 15 | $202.59 | 15% |
Adam Bieniak and Krzysztof Bieniak hold a combined 85% – the ownership structure indicates family control.
Beneficial owners
| Person | Rights |
|---|---|
Debt
No entries in the National Debtors Register (KRZ).
Public aid
4 public aid cases recorded, with a total value of $30,545.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jan 4, 2021 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $4,488$4,488 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Jan 4, 2021 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $4,299$4,299 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Jan 4, 2021 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $4,025$4,025 | Prezes Zakładu Ubezpieczeń Społecznych |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Medikon Polskasp. z o.o. | $2,666,944.24 | medikon.pl | ||
| American Way Polska Miłkowskisp. k. | $1,893,749.17 | americanwaypolska.pl | ||
| Brandexsp. z o.o. | $1,958,619.75 | brandex.pl | ||
| PUBE Globalsp. z o.o. | $1,777,827.09 | pubeglobal.com | ||
| Tricopat Globalsp. z o.o. | $1,772,824.41 | tricopatglobal.com | ||
| Novicaresp. z o.o. | $1,512,398.66 | novicare.pl | ||
| Dental Solutionssp. z o.o. | $611,683.37 | dentalsolutions.pl | ||
| Beauty Care Solutionsp. z o.o. | $391,209.94 | ohhira.pl | ||
| Aimedicalsp. z o.o. | $240,059.72 | aimedical.pl | ||
| Vorwarts Pharmasp. z o.o. | $210,138.62 | vorwartspharma.pl |
FAQ
Last updated: 2026-06-30